Base de dados : MEDLINE
Pesquisa : D03.066.515.950 [Categoria DeCS]
Referências encontradas : 220 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 22 ir para página                         

  1 / 220 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26718554
[Au] Autor:Bai X; Huang L; Hu K; Qu F
[Ad] Endereço:Department of Pharmacy, The Second Affiliated Hospital of Harbin Medical University, 148 Baojian Road, Harbin, 150086, Heilongjiang Province, China.
[Ti] Título:Inhibited proliferation of human umbilical artery smooth muscle cells by xanthinol nicotinate.
[So] Source:Med Biol Eng Comput;54(6):891-8, 2016 Jun.
[Is] ISSN:1741-0444
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Vascular smooth muscle cell proliferation is a key event in the development of hypertension, instant restenosis and other cardiac disorders. Inhibition of this proliferation could lead to better prevention and treatment of these diseases. This study was designed to investigate the effects and mechanisms of different concentrations of xanthinol nicotinate (XN) on human umbilical artery smooth muscle cell (HUASMC) proliferation in vitro. HUASMCs were cultured by the tissue adherent method, passaged three times, and then identified by immunohistochemistry. HUASMCs were then treated with different concentrations of XN (0, 2.76, 27.6 or 276 µM), and a 3-(4,5-dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was used to detect the inhibition of HUASMC proliferation. The levels of platelet-derived growth factor receptor (PDGFR) mRNA and protein (PDGFR-ß) were detected on the cell membrane of these treated HUASMCs using RT-PCR and Western blot analysis, respectively. After culturing and passaging three times, 90 % of the cultured cells were identified as HUASMCs by immunohistochemistry. HUASMC proliferation was inhibited by XN in a dose-dependent manner (P < 0.05). Furthermore, XN dose-dependently decreased the PDGFR mRNA and PDGFR-ß levels on the cell membranes of HUASMCs (P < 0.05). Thus, the results suggest that XN could become a potent therapeutic agent for regulating VSMC-associated vascular disease such as cardiovascular disease and restenosis after angioplasty.
[Mh] Termos MeSH primário: Miócitos de Músculo Liso/citologia
Artérias Umbilicais/citologia
Niacinato de Xantinol/farmacologia
[Mh] Termos MeSH secundário: Contagem de Células
Membrana Celular/efeitos dos fármacos
Membrana Celular/metabolismo
Proliferação Celular/efeitos dos fármacos
Células Cultivadas
Regulação para Baixo/efeitos dos fármacos
Seres Humanos
Imuno-Histoquímica
Miócitos de Músculo Liso/efeitos dos fármacos
Miócitos de Músculo Liso/metabolismo
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Receptor beta de Fator de Crescimento Derivado de Plaquetas/genética
Receptor beta de Fator de Crescimento Derivado de Plaquetas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (RNA, Messenger); 8G60H12X2D (Xanthinol Niacinate); EC 2.7.10.1 (Receptor, Platelet-Derived Growth Factor beta)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171104
[Lr] Data última revisão:
171104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160101
[St] Status:MEDLINE
[do] DOI:10.1007/s11517-015-1438-9


  2 / 220 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:22650099
[Au] Autor:Zivic L; Zivic D; Djonovic N
[Ti] Título:[Sudden hearing loss: our experiences in treatment with vasoactive and corticosteroid therapy].
[So] Source:Srp Arh Celok Lek;140(3-4):153-8, 2012 Mar-Apr.
[Is] ISSN:0370-8179
[Cp] País de publicação:Serbia
[La] Idioma:srp
[Ab] Resumo:INTRODUCTION: Sudden hearing loss is a clinical entity of ambiguously defined aetiology manifested by hearing loss of more than 30 dB on three contiguous frequencies occurring within 72 hours. The lack of standard therapy protocol led to the use of variety of different therapies, thus making difficult objective quantification of their effect. OBJECTIVE: The aim of the study was to present our experience in the treatment of sudden hearing loss with administration of vasoactive and corticosteroid therapy. METHODS: Our research included 59 hospitally treated patients with a sudden hearing loss. During the period 1995-2004, 37 patients were treated using vasoactive agents (xanthinol nicotinate and pentoxifylline), and from 2004-2009, 22 patients were treated using parenteral corticosteroids (dexamethasone). All patients had unilateral sensorineural hearing loss of different level at frequencies from 500-4000 Hz, while other diagnostic procedures (laboratory tests, internist and neurology examinations, X-ray) were within normal limits. Evaluation of therapy effect was done by follow-up of hearing threshold changes and subjective complaints. RESULTS: The results showed that full recovery was achieved in patients with a mild and not fully severe hearing loss, with the majority of those (73%) under corticosteroid treatment. In these patients recovery was also achieved more rapidly. A partial recovery of hearing was detected in patients with hearing loss of more than 80 dB, and mostly in patients treated with corticosteroids. CONCLUSION: Although statistical evaluation does not indicate significant differences between the application of vasoactive drugs or corticosteroids, clinical findings support advantages of corticosteroid therapy. Treatment of hearing loss, although controversial, requires change of some up-to-now used agents. Advantages should go in favour of contricosteroids.
[Mh] Termos MeSH primário: Dexametasona/uso terapêutico
Glucocorticoides/uso terapêutico
Perda Auditiva Neurossensorial/tratamento farmacológico
Perda Auditiva Súbita/tratamento farmacológico
Pentoxifilina/uso terapêutico
Vasodilatadores/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Feminino
Perda Auditiva Súbita/diagnóstico
Seres Humanos
Masculino
Niacinato de Xantinol/uso terapêutico
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Vasodilator Agents); 7S5I7G3JQL (Dexamethasone); 8G60H12X2D (Xanthinol Niacinate); SD6QCT3TSU (Pentoxifylline)
[Em] Mês de entrada:1206
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120602
[St] Status:MEDLINE


  3 / 220 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:21983458
[Au] Autor:Kuznetsov MR; Rodionov SV; Koshkin VM; Virganskii AO; Golosnitskii PIu; Tepliakov SA; Kosykh IV; Ostapchuk NA; Lisenkov OP; Chernikov VP
[Ti] Título:[Role of low-dose acetylsalicylic acid in comprehensive postoperative treatment of patients with lower-limb chronic arterial insufficiency].
[So] Source:Angiol Sosud Khir;17(2):23-9, 2011.
[Is] ISSN:1027-6661
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The study comprised a total of 107 patients (all men) after endured femoropopliteal bypass grafting above the genicular fissure with a synthetic stent graft manufactured by the Gore Company for stage IIB and III chronic arterial insufficiency of the lower extremities according to the Fontain-Pokrovsky classification. Group One I (control group) was composed of fifty-four patients permanently taking in the postoperative period at the out-patient stage pentoxiphylline (trental 400 mg 1 tablet 3 times daily) and xantinol nicotinate at a dose of 150 mg one tablet thrice daily. Group Two (Study Group) consisted of fifty-three patients taking after reconstructive vascular surgery at the out-patient stage in addition to pentoxiphylline and xantinol nicotinate acetylsalicylic acid (cardiomagnil 75 mg 1 tablet once daily). The Control Group patients within 3 to 6 months of follow up were found to have a considerable progressing improvement of the functional abilities of the microcirculatory bed requiring in 44 (81.5%) cases hospitalization to the Surgical Department for intensive vascular therapy. Despite this fact four (7.4%) patients within the time frame from 6 to 9 months after surgery developed thrombosis of the vascular implant requiring a repeat surgical intervention. In the Study Group patients, the degree of functional capabilities of the microcirculatory bed in the postoperative period was less considerable, reaching the maximum after 10-12 months of follow up, with eighteen (34.0%) patients requiring hospitalization for additional vascular therapy to perform. There were no cases of implants' thrombosis in the Study Group patients. Pathological alterations in the functional state of the peripheral vascular bed correlated with viscosimetric indices and activity of blood platelet aggregation. The addition of antithrombocytic agents to conservative postoperative therapy considerably improved the outcomes of surgical treatment.
[Mh] Termos MeSH primário: Aspirina
Artéria Femoral
Oclusão de Enxerto Vascular/prevenção & controle
Doença Arterial Periférica/cirurgia
Artéria Poplítea
Enxerto Vascular/efeitos adversos
[Mh] Termos MeSH secundário: Aspirina/administração & dosagem
Aspirina/efeitos adversos
Coagulação Sanguínea/efeitos dos fármacos
Viscosidade Sanguínea/efeitos dos fármacos
Artéria Femoral/patologia
Artéria Femoral/transplante
Oclusão de Enxerto Vascular/sangue
Oclusão de Enxerto Vascular/etiologia
Oclusão de Enxerto Vascular/patologia
Seres Humanos
Extremidade Inferior/irrigação sanguínea
Masculino
Pentoxifilina/administração & dosagem
Pentoxifilina/efeitos adversos
Doença Arterial Periférica/sangue
Doença Arterial Periférica/patologia
Agregação Plaquetária/efeitos dos fármacos
Inibidores da Agregação de Plaquetas/administração & dosagem
Inibidores da Agregação de Plaquetas/efeitos adversos
Artéria Poplítea/patologia
Artéria Poplítea/transplante
Período Pós-Operatório
Reoperação
Resultado do Tratamento
Enxerto Vascular/métodos
Grau de Desobstrução Vascular/efeitos dos fármacos
Vasodilatadores/administração & dosagem
Vasodilatadores/efeitos adversos
Niacinato de Xantinol/administração & dosagem
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Platelet Aggregation Inhibitors); 0 (Vasodilator Agents); 8G60H12X2D (Xanthinol Niacinate); R16CO5Y76E (Aspirin); SD6QCT3TSU (Pentoxifylline)
[Em] Mês de entrada:1112
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:111011
[St] Status:MEDLINE


  4 / 220 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:21427993
[Au] Autor:Kovalev VA; Karaguzhin SK; Abdulkhamidov AN; Danovich VM; Kyzlasov PS; Matskevich SV
[Ti] Título:[Peyronie's disease: comparative results of conservative treatment].
[So] Source:Urologiia;(6):40-4, 2010 Nov-Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Long-term clinical experience with conservative treatment of Peyronie's disease has demonstrated that clinical efficacy of this therapy comprises maily anesthesia while erectile problems are not solved. Introduction of the drugs into the fibrous plaque is not adequate and hard to perform. Some drugs affect only some components of pathogenesis. For stabilization of the process it is recommended to use transdermal electrophoresis or phonophoresis. The search for new effective drugs and methods continues.
[Mh] Termos MeSH primário: Corticosteroides/uso terapêutico
Interferon-alfa/uso terapêutico
Induração Peniana/tratamento farmacológico
Verapamil/uso terapêutico
Niacinato de Xantinol/uso terapêutico
[Mh] Termos MeSH secundário: Administração Cutânea
Corticosteroides/administração & dosagem
Eletroporação
Seres Humanos
Interferon-alfa/administração & dosagem
Masculino
Meia-Idade
Dor/prevenção & controle
Fonoforese
Proteínas Recombinantes
Resultado do Tratamento
Verapamil/administração & dosagem
Niacinato de Xantinol/administração & dosagem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Interferon-alpha); 0 (Recombinant Proteins); 43K1W2T1M6 (interferon alfa-2b); 8G60H12X2D (Xanthinol Niacinate); CJ0O37KU29 (Verapamil)
[Em] Mês de entrada:1104
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110325
[St] Status:MEDLINE


  5 / 220 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:19585554
[Au] Autor:Segers J; Crokart N; Danhier P; Grégoire V; Jordan BF; Gallez B
[Ad] Endereço:Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium.
[Ti] Título:Use of Xanthinol Nicotinate as a co-treatment for radio- and chemo-therapy in experimental tumors.
[So] Source:Int J Cancer;126(2):583-8, 2010 Jan 15.
[Is] ISSN:1097-0215
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The tumor micro-environment plays a key role in the tumor resistance to cytotoxic treatments. It has been demonstrated that it is possible to modulate the tumor microenvironment to potentiate anti-cancer therapy. Here, we made the hypothesis that the vasoactive agent xanthinol nicotinate (XN) could be an important modulator of the tumor perfusion and oxygenation. Using functional non invasive techniques (in vivo EPR oximetry and dynamic contrast enhanced MRI), we were able to define a time window in which tumor oxygenation, flow and permeability were significantly increased in the TLT tumor model implanted in muscles of mice. As a consequence of the alleviation of tumor hypoxia, we found out that XN was able to radiosensitize the tumors when applying 10 Gy of X-Rays during the reoxygenation of the tumors (enhancement in radiation response of 1.4). Moreover, the administration of cyclosphosphamide (50 mg/kg) used as a chemotherapeutic agent was more efficient when applying the treatment after XN administration (enhancement in response to chemotherapy of 2.7). These results show the importance of the dynamic evolution of the tumor microenvironment on the response to treatments, and that XN is an efficient modulator of the tumor hemodynamics that may potentiate cytotoxic treatments.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias Experimentais/tratamento farmacológico
Radiossensibilizantes/farmacologia
Niacinato de Xantinol/farmacologia
[Mh] Termos MeSH secundário: Animais
Antineoplásicos Alquilantes/administração & dosagem
Terapia Combinada
Ciclofosfamida/uso terapêutico
Hemodinâmica/efeitos dos fármacos
Hemodinâmica/efeitos da radiação
Imagem por Ressonância Magnética
Masculino
Camundongos
Camundongos Endogâmicos
Neoplasias Experimentais/patologia
Neoplasias Experimentais/radioterapia
Radiossensibilizantes/administração & dosagem
Fatores de Tempo
Resultado do Tratamento
Carga Tumoral/efeitos dos fármacos
Carga Tumoral/efeitos da radiação
Vasodilatadores/farmacologia
Terapia por Raios X/métodos
Niacinato de Xantinol/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 0 (Radiation-Sensitizing Agents); 0 (Vasodilator Agents); 8G60H12X2D (Xanthinol Niacinate); 8N3DW7272P (Cyclophosphamide)
[Em] Mês de entrada:1001
[Cu] Atualização por classe:160303
[Lr] Data última revisão:
160303
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090709
[St] Status:MEDLINE
[do] DOI:10.1002/ijc.24724


  6 / 220 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:19355959
[Au] Autor:Kucherov II; Rytik PG; Podol'skaya IA; Mistryukova LO; Korjev MO
[Ad] Endereço:State Scientific Research Institute of Epidemiology and Microbiology, Ministry of Health of Belarus, Minsk, Belarus.
[Ti] Título:Novel inhibitors of HIV discovered among existing classes of pharmaceutical compounds indicated for unrelated clinical indications.
[So] Source:Curr Pharm Des;15(11):1187-90, 2009.
[Is] ISSN:1873-4286
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:In vitro screening of 307 drugs with various clinical indications (cardiotropic, neurotropic, antibacterial, etc.) has revealed 6 compounds which displayed remarkable antiretroviral activity. Three of these drugs had a tendency to have undesirable side effects and were thus excluded from further consideration. Remaining three, i.e., Xantinol Nicotinate, Tardiferon, and Trental may become valid candidates for inclusion into antiviral regimens such as HAART. In vitro tests have shown that xantinol and trental display synergistic effect with azidothymidine, inhibit the replication AZT-resistant strains of HIV, and have no competing undesirable activities. These compounds should be evaluated in safety studies to determine optimal doses for patients with HIV. If these studies confirm in vitro results these compounds may become valid candidates as safe and affordable means to be added into the arsenal of antiretroviral drugs.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/farmacologia
Compostos Ferrosos
Mucinas
Pentoxifilina
Vasodilatadores/farmacologia
Niacinato de Xantinol
[Mh] Termos MeSH secundário: Animais
Fármacos Anti-HIV/uso terapêutico
Combinação de Medicamentos
Infecções por HIV/tratamento farmacológico
Seres Humanos
Vasodilatadores/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (Drug Combinations); 0 (Ferrous Compounds); 0 (Mucins); 0 (Vasodilator Agents); 75285-30-2 (ferrous sulfate, mucin drug combination); 8G60H12X2D (Xanthinol Niacinate); SD6QCT3TSU (Pentoxifylline)
[Em] Mês de entrada:0907
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090410
[St] Status:MEDLINE


  7 / 220 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:18720739
[Au] Autor:Zivic L; Zivic D; Stojanovic S
[Ti] Título:[Sudden hearing loss--our experience in treatment with vasoactive therapy].
[So] Source:Srp Arh Celok Lek;136(3-4):91-4, 2008 Mar-Apr.
[Is] ISSN:0370-8179
[Cp] País de publicação:Serbia
[La] Idioma:srp
[Ab] Resumo:INTRODUCTION: A specific title "sudden hearing loss" refers to illness which is characterized by a sudden, rapid sensoneural hearing loss mostly in one ear without obvious causes, accompanied with dizziness, and without vestibular symptomatology. It is defined as a hearing loss for more than 30 dB on 3 or more successive frequencies which appear in 72 hours. OBJECTIVE: The main goal of our paper was to estimate success of implementation of vasoactive method in patients with sudden hearing loss of senso-neural type in different ranges in hospital conditions. METHOD: Our research covered 37 patients hospitalized because of a sudden hearing loss of sensoneural type in different ranges. Diagnosis, in all patients, was established by clinical ORL examination, audiology and vestibular examination. R including CT and MR, neurological, internist and laboratory examinations were used in order to exclude other aetiology. In monitored patients, we started treatment with vasoactive therapy, ampules of xanthinol nicotinate (one ampule of 2 ml, 300 mg) or ampules of pentoxiphylline (one ampule of 5 ml, 100 mg) in form of infusions with addition of vitamins with an everyday gradual increase of dosage up to 12 ampules of xanthinol nicotinate and up to 5 ampules of pentoxiphylline. Then we started with an everyday decrease of dosage down to the first one. RESULTS: After the complete curing protocol, we found out that in patients with light and medium senso-neural damages of hearing sense (23 or 62%), hearing recovery was complete. In patients with heavy damage of hearing (9 or 24%), partial success was evidenced. The most difficult cases, with complete hearing loss, heavy buzzing and vertiginous problem (5 or 14%) responded to therapy, so buzzing and vertiginous problems disappeared but hearing was not improved. CONCLUSION: Usage of vasoactive medicaments in hospital conditions in treatment of sudden hearing loss gives good results and it is the closest to aetiological therapy.
[Mh] Termos MeSH primário: Perda Auditiva Neurossensorial/tratamento farmacológico
Perda Auditiva Súbita/tratamento farmacológico
Pentoxifilina/uso terapêutico
Vasodilatadores/uso terapêutico
Niacinato de Xantinol/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Feminino
Perda Auditiva Neurossensorial/fisiopatologia
Perda Auditiva Súbita/fisiopatologia
Seres Humanos
Masculino
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Vasodilator Agents); 8G60H12X2D (Xanthinol Niacinate); SD6QCT3TSU (Pentoxifylline)
[Em] Mês de entrada:0809
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080830
[St] Status:MEDLINE


  8 / 220 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:18718822
[Au] Autor:Liu HQ; Su MX; Di B; Hang TJ; Hu Y; Tian XQ; Zhang YD; Shen JP
[Ad] Endereço:Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, PR China.
[Ti] Título:Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of xanthinol in human plasma and its application in a bioequivalence study of xanthinol nicotinate tablets.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;873(1):20-6, 2008 Sep 15.
[Is] ISSN:1570-0232
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A sensitive, rapid liquid chromatographic-electrospray ionization mass spectrometric method for the determination of xanthinol in human plasma was developed and validated. Xanthinol nicotinate in plasma (0.5 mL) was pretreated with 20% trichloroacetic acid for protein precipitation. The samples were separated using a Lichrospher silica (5 microm, 250 mm x 4.6 mm i.d.). A mobile phase of methanol-water containing 0.1% formic acid (50: 50, v/v) was used isocratically eluting at a flow rate of 1 mL/min. Xanthinol and its internal standard (IS), acyclovir, were measured by electrospray ion source in positive selected reaction monitoring mode. The method demonstrated that good linearity ranged from 10.27 to 1642.8 ng/mL with r=0.9956. The limit of quantification for xanthinol in plasma was 10.27 ng/mL with good accuracy and precision. The mean plasma extraction recovery of xanthinol was in the range of 90.9-100.2%. The intra- and inter-batch variability values were less than 4.8% and 7.9% (relative standard deviation, R.S.D.), respectively. The established method has been successfully applied to a bioequivalence study of two xanthinol nicotinate tablets for 20 healthy volunteers.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Niacinato de Xantinol/farmacocinética
[Mh] Termos MeSH secundário: Estabilidade de Medicamentos
Seres Humanos
Reprodutibilidade dos Testes
Espectrometria de Massas por Ionização por Electrospray/métodos
Espectrometria de Massas em Tandem/métodos
Equivalência Terapêutica
Incerteza
Niacinato de Xantinol/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
8G60H12X2D (Xanthinol Niacinate)
[Em] Mês de entrada:0811
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080823
[St] Status:MEDLINE
[do] DOI:10.1016/j.jchromb.2008.07.045


  9 / 220 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:12353381
[Au] Autor:Miller DA
[Ad] Endereço:State Medical Academy, Tver.
[Ti] Título:[Pathogenetic basis for using prodectin and teonicol, redergin and aescuzan in complex treatment of chronic gastritis].
[Ti] Título:Patogeneticheskie osnovy primeneniia prodektina i teonikola, redergina i éskuzana pri kompleksnom lechenii khronicheskogo gastrita..
[So] Source:Eksp Klin Gastroenterol;(3):22-5, 118, 2002.
[Is] ISSN:1682-8658
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The study of the microvessels in bioptates of gastric mucosa and micro haemocirculation in the conjunctiva of 254 patients with chronic gastritis revealed that exacerbation of the gastric process is going on the background of hard terminal bloodstream disorders. They have the generalized character and picture of the typical chronic relapsing trombohaemorrhagic syndrome. The use of Prodectin (250 mg), Teonicolum (150 mg), Redergin (1 tab.) and Aescuzan (25 dr.) 4 times per day during 3 weeks helps to eliminate the microcirculatory disorders and exacerbation of the chronic gastritis.
[Mh] Termos MeSH primário: Mesilatos Ergoloides/uso terapêutico
Escina/uso terapêutico
Gastrite/tratamento farmacológico
Fármacos Gastrointestinais/uso terapêutico
Piridinolcarbamato/uso terapêutico
Niacinato de Xantinol/uso terapêutico
[Mh] Termos MeSH secundário: Quimioterapia Combinada
Mesilatos Ergoloides/administração & dosagem
Escina/administração & dosagem
Feminino
Fármacos Gastrointestinais/administração & dosagem
Seres Humanos
Masculino
Meia-Idade
Piridinolcarbamato/administração & dosagem
Niacinato de Xantinol/administração & dosagem
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Gastrointestinal Agents); 6805-41-0 (Escin); 8067-24-1 (Ergoloid Mesylates); 81R511UV73 (Pyridinolcarbamate); 8G60H12X2D (Xanthinol Niacinate)
[Em] Mês de entrada:0211
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:021002
[St] Status:MEDLINE


  10 / 220 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:11737454
[Au] Autor:Rosina P; Chieregato C; Miccolis D; D'Onghia FS
[Ad] Endereço:Section of Dermatology and Venereology, Department of Biomedical and Surgical Sciences, University of Verona, Italy. prosina@yahoo.com
[Ti] Título:Psoriasis and side-effects of mesotherapy.
[So] Source:Int J Dermatol;40(9):581-3, 2001 Sep.
[Is] ISSN:0011-9059
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Aminofilina/efeitos adversos
Anestésicos Locais/efeitos adversos
Lidocaína/efeitos adversos
Psoríase/patologia
Vasodilatadores/efeitos adversos
Niacinato de Xantinol/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Aminofilina/administração & dosagem
Anestésicos Locais/administração & dosagem
Ciclosporina/uso terapêutico
Fármacos Dermatológicos/uso terapêutico
Quimioterapia Combinada
Feminino
Seres Humanos
Injeções Intradérmicas/efeitos adversos
Lidocaína/administração & dosagem
Psoríase/tratamento farmacológico
Ciática/tratamento farmacológico
Vasodilatadores/administração & dosagem
Niacinato de Xantinol/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anesthetics, Local); 0 (Dermatologic Agents); 0 (Vasodilator Agents); 27Y3KJK423 (Aminophylline); 83HN0GTJ6D (Cyclosporine); 8G60H12X2D (Xanthinol Niacinate); 98PI200987 (Lidocaine)
[Em] Mês de entrada:0201
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:011212
[St] Status:MEDLINE



página 1 de 22 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde